1. Search Result
Search Result
Results for "

liver function

" in MedChemExpress (MCE) Product Catalog:

69

Inhibitors & Agonists

6

Screening Libraries

4

Fluorescent Dye

5

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

19

Natural
Products

6

Isotope-Labeled Compounds

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147041

    GB1211

    Galectin Inflammation/Immunology Cancer
    Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis .
    Selvigaltin
  • HY-W007330

    Aldehyde Dehydrogenase (ALDH) Microtubule/Tubulin Metabolic Disease
    2-Bromoacetamide is a disinfection byproduct. 2-Bromoacetamide can inactivate liver alcohol dehydrogenase and interfere with microtubule and actin cytoskeletal function. 2-Bromoacetamide is a potent developmental toxicant in animals .
    2-Bromoacetamide
  • HY-D0711
    Indocyanine green
    30+ Cited Publications

    Foxgreen; IC Green; Cardiogreen

    Fluorescent Dye Cancer
    Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography (Ex/Em = 785/813 nm) .
    Indocyanine green
  • HY-114118
    Semaglutide
    20+ Cited Publications

    GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide
  • HY-114118B
    Semaglutide acetate
    20+ Cited Publications

    GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide acetate
  • HY-Y1840

    Others Neurological Disease
    3-Methoxyphenol is a phenolic compound that is biologically toxic. 3-Methoxyphenol is systemically absorbed, disrupts the function of the liver, kidneys, central nervous system, and redox processes, and increases levels of Hb, red blood cells, and white blood cells in the body.
    3-Methoxyphenol
  • HY-119722

    Endogenous Metabolite Others
    Butafosfan is a phosphate containing compound, which is used as active ingredient of veterinary drug. Butafosfan can stimulate the appetite, immune system and digestive function, improves liver and muscle function of dogs. Butafosfan can mitigate the adverse effects of Dexamethasone (HY-14648) on liver and pancreatic function in dogs .
    Butafosfan
  • HY-N15829

    Fluorescent Dye Metabolic Disease
    Cholyl-Lys-fluorescein sodium is a fluorescein-labeled bile acid analog. Cholyl-Lys-fluorescein sodium can be used for biliary atresia validation and for determining in vivo liver function .
    Cholyl-Lys-fluorescein sodium
  • HY-164221A

    ALN-HSD sodium

    17β-HSD Metabolic Disease
    Rapirosiran sodium is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran sodium can be used for the study of Non-alcoholic steatohepatitis.
    Rapirosiran sodium
  • HY-164221

    ALN-HSD; ALN-288996; AD-288996

    17β-HSD Metabolic Disease
    Rapirosiran is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran can be used for the study of Non-alcoholic steatohepatitis.
    Rapirosiran
  • HY-114118F

    GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide, FITC labeled is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide, FITC labeled
  • HY-114118S1

    Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8 tetraTFA
  • HY-114118A
    Semaglutide TFA
    20+ Cited Publications

    GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide TFA
  • HY-114118S

    Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8
  • HY-B0848
    Tricyclazole
    2 Publications Verification

    Fungal Infection Metabolic Disease
    Tricyclazole is a pentaketone melanin biosynthesis inhibitor and a unique fungicide for controlling rice blast. Tricyclazole alters the structure and function of fungal cell walls, reduces fungal pathogenicity and penetration, and causes dose-dependent liver damage in animals .
    Tricyclazole
  • HY-173383

    1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt

    Biochemical Assay Reagents Inflammation/Immunology Cancer
    DOPE-DOTA sodium is a chelated lipid that serves as a key contrast agent in magnetic resonance imaging (MRI). DOPE-DOTA sodium can be used for cancer, blood-brain barrier disruption, abnormalities such as aneurysms or plaque buildup, inflammation in arthritis, and liver function and lesions study
    DOPE-DOTA sodium
  • HY-174669

    mRNA Cancer
    Human HNF1A mRNA encodes the human HNF1 homeobox A (HNF1A) protein, a transcription factor that required for the expression of several liver-specific genes. HNF1A functions as a homodimer and binds to the inverted palindrome 5''-GTTAATNATTAAC-3''.
    Human HNF1A mRNA
  • HY-B1684

    SQ 26962

    Biochemical Assay Reagents Others
    Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .
    Mebrofenin
  • HY-B1684R

    SQ 26962 (Standard)

    Biochemical Assay Reagents Reference Standards Others
    Mebrofenin (Standard) is the analytical standard of Mebrofenin. This product is intended for research and analytical applications. Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .
    Mebrofenin (Standard)
  • HY-N2334A
    Glycochenodeoxycholic acid sodium salt
    5 Publications Verification

    Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate

    Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    Glycochenodeoxycholic acid sodium salt
  • HY-N2334
    Glycochenodeoxycholic acid
    5 Publications Verification

    Chenodeoxycholylglycine

    Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    Glycochenodeoxycholic acid
  • HY-D0711R

    Foxgreen (Standard); IC Green (Standard); Cardiogreen (Standard)

    Fluorescent Dye Reference Standards Others
    Indocyanine green (Standard) is the analytical standard of Indocyanine green. This product is intended for research and analytical applications. Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography .
    Indocyanine green (Standard)
  • HY-114118S3

    Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Metabolic Disease
    Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-13C6,15N TFA
  • HY-D0711S2

    Foxgreen-d7; IC Green-d7; Cardiogreen-d7

    Isotope-Labeled Compounds Fluorescent Dye Others
    Indocyanine green-d7 (Foxgreen-d7) is the deuterium labeled Indocyanine green (HY-D0711). Indocyanine green is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography .
    Indocyanine green-d7
  • HY-B0817
    Pyridaben
    1 Publications Verification

    Parasite Infection
    Pyridaben is a mitochondrial electron transport inhibitor (METI) acaricide that promotes the formation of damaging oxygen and nitrogen radicals. Pyridaben selectively inhibits complex I (NADH dehydrogenase) with an IC50 value of 2.4 nM (assay sites: rat liver and bovine heart mitochondria). Pyridaben also significantly inhibits rat mitochondrial mtNOS function .
    Pyridaben
  • HY-108292

    Others Cancer
    Propacetamol hydrochloride is an analgesic agent, can be used in induction of acute liver injury. Propacetamol hydrochloride acts function through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress. Propacetamol hydrochloride also is a precursor form of paracetamol. Propacetamol hydrochloride can be used in postoperative pain, acute trauma and gastrointestinal disorders .
    Propacetamol hydrochloride
  • HY-N2334R

    Chenodeoxycholylglycine (Standard)

    Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid (Standard) is the analytical standard of Glycochenodeoxycholic acid. This product is intended for research and analytical applications. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].
    Glycochenodeoxycholic acid (Standard)
  • HY-138813R

    SU-12662 hydrochloride (Standard)

    Reference Standards Drug Metabolite Cancer
    Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    N-Desethyl Sunitinib hydrochloride (Standard)
  • HY-N2334AR

    Chenodeoxycholylglycine sodium salt (Standard); Sodium glycochenodeoxycholate (Standard)

    Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    Glycochenodeoxycholic acid sodium salt (Standard)
  • HY-B0998

    Dehydrocholate sodium

    Amylases Lipase Autophagy Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid sodium
  • HY-169957

    Reactive Oxygen Species (ROS) Cancer
    ROS-ERS inducer 2 (Complex 3f) triggers intracellular ROS generation and affect the function of mitochondria. promote the release of damage-associated molecular patterns (DAMPs), induce immunogenic cell death (ICD) and activates endoplasmic reticulum stress (ERS). ROS-ERS inducer 2 plays an important role in anti-liver cancer research .
    ROS-ERS inducer 2
  • HY-D1734

    LXR Cardiovascular Disease
    FITC-GW3965 is a fluorescence-labelled liver X receptor β (LXRβ) agonist GW3965 (HY-10627). FITC-GW3965 is a tracer, that can be designed by replacing the trifluoromethyl of GW3965 with an amide to link the FITC. FITC-GW3965 can be used to study the function of LXRβ .
    FITC-GW3965
  • HY-A0282

    Amino Acid Derivatives Metabolic Disease Inflammation/Immunology
    L-Ornithine L-aspartate is a stable salt of two natural nonessential L-amino acids with oral activity: ornithine and aspartic acid. L-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis. L-Ornithine L-aspartate also improves mitochondrial functions .
    L-Ornithine L-aspartate
  • HY-B1393

    Dehydrocholate

    Autophagy Amylases Lipase Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid
  • HY-Y1840R

    Biochemical Assay Reagents Reference Standards Neurological Disease
    3-Methoxyphenol (Standard) is the analytical standard of 3-Methoxyphenol. This product is intended for research and analytical applications. 3-Methoxyphenol is a phenolic compound that is biologically toxic. 3-Methoxyphenol is systemically absorbed, disrupts the function of the liver, kidneys, central nervous system, and redox processes, and increases levels of Hb, red blood cells, and white blood cells in the body.
    3-Methoxyphenol (Standard)
  • HY-W424918

    Dopamine Receptor Neurological Disease
    Opromazine hydrochloride is an antipsychotic medication that exhibits sedative and antiemetic pharmacological effects, making it effective for treating psychiatric disorders such as schizophrenia and psychosis. Opromazine hydrochloride functions by reducing dopaminergic activity through the blockade of dopamine receptors in the brain. Opromazine hydrochloride has been analyzed for its metabolites in various microsomal enzymes, revealing differences in formation rates that underscore the variability of drug-metabolizing enzymes in human liver and placenta microsomes.
    Opromazine hydrochloride
  • HY-Y1840S

    Isotope-Labeled Compounds Neurological Disease
    3-Methoxyphenol-d3 is deuterated labeled 3-Methoxyphenol (HY-Y1840). 3-Methoxyphenol is a phenolic compound that is biologically toxic. 3-Methoxyphenol is systemically absorbed, disrupts the function of the liver, kidneys, central nervous system, and redox processes, and increases levels of Hb, red blood cells, and white blood cells in the body.
    3-Methoxyphenol-d3
  • HY-B0817S

    Parasite Infection
    Pyridaben-d13 is the deuterium labeled Pyridaben . Pyridaben is a mitochondrial electron transport inhibitor (METI) acaricide that promotes the formation of damaging oxygen and nitrogen radicals. Pyridaben selectively inhibits complex I (NADH dehydrogenase) with an IC50 value of 2.4 nM (assay sites: rat liver and bovine heart mitochondria). Pyridaben also significantly inhibits rat mitochondrial mtNOS function .
    Pyridaben-d13
  • HY-W075903

    Cobalt hexammine trichloride; Hexaamminecobalt trichloride

    Biochemical Assay Reagents SOD Glutathione S-transferase Metabolic Disease Cancer
    Hexaamminecobalt (III) chloride is an orally active cobalt coordination compound. Hexaamminecobalt (III) chloride restores the activities of liver antioxidant enzymes (SOD, Catalase) and detoxification enzyme GST. Hexaamminecobalt (III) chloride restores GSH content and reduces DAG. Hexaamminecobalt (III) chloride impairs renal function. Hexaamminecobalt (III) chloride exerts anti-carcinogenic effects in Diethylnitrosamine (HY-N7434)-induced hepatocarcinoma .
    Hexaamminecobalt(III) chloride
  • HY-16121

    Cathepsin Others
    CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC50 value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites [1][2][3].
    CAA-0225
  • HY-B0817R

    Reference Standards Parasite Infection
    Pyridaben (Standard) is the analytical standard of Pyridaben. This product is intended for research and analytical applications. Pyridaben is a mitochondrial electron transport inhibitor (METI) acaricide that promotes the formation of damaging oxygen and nitrogen radicals. Pyridaben selectively inhibits complex I (NADH dehydrogenase) with an IC50 value of 2.4 nM (assay sites: rat liver and bovine heart mitochondria). Pyridaben also significantly inhibits rat mitochondrial mtNOS function .
    Pyridaben (Standard)
  • HY-167681

    Ro 12-4713

    Endogenous Metabolite Cardiovascular Disease
    Carprazidil (Ro 12-4713) is a potent vasodilator with activity in suppressing severe hypertension and mild heart failure. The use of carprazidil may lead to sodium retention and increased heart rate, requiring increased doses of diuretics or beta-blockers in some cases. Carprazidil and mecycline may both cause hirsutism, limiting their long-term use in women. Carprazidil did not cause adverse side effects on hematological parameters, liver, or kidney function .
    Carprazidil
  • HY-W014120

    Biochemical Assay Reagents Parasite Infection
    Thianthrene is a potent and orally active inhibitor of Leishmania donovani pteridine reductase 1 (PTR1). Thianthrene is a sulfur-containing tricyclic molecule distributed widely within the macro-structure of hydrocarbon fossil fuels. Thianthrene inhibits the intracellular amastigotes of Leishmania donovani (IC50 = 23 μM). Thianthrene has a moderate anthelmintic activity. Thianthrene appears to inhibit RNA function and subsequent protein production. Thianthrene can stimulate liver regeneration in vivo .
    Thianthrene
  • HY-125469

    PF-04895162

    Potassium Channel Neurological Disease
    ICA-105665 (PF-04895162) is a potent and orally active neuronal Kv7.2/7.3 and Kv7.3/7.5 potassium channels opener. ICA-105665 inhibits liver mitochondrial function and bile salt export protein (BSEP) transport (IC50 of 311 μM). ICA-105665 can penetrate the blood-brain barrier and has antiseizure effects .
    ICA-105665
  • HY-B1393R

    Dehydrocholate (Standard)

    Reference Standards Autophagy Amylases Lipase Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) (Standard) is the analytical standard of Dehydrocholic acid (HY-B1393). This product is intended for research and analytical applications. Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid (Standard)
  • HY-N7860

    Others Infection
    Δ2-cis Eicosenoic acid is an α,β-unsaturated fatty acid that has been extracted from fresh water clams and purified. A related compound, 2-octadecenoic acid, has been shown to improve liver function and decrease blood sugar in streptozocin-induced diabetic rats. Δ2-cis Eicosenoic acid and its salts have potential medicinal use for treating diabetes and improving lipid metabolism.
    Δ2-cis Eicosenoic acid
  • HY-14353

    LXR Neurological Disease Inflammation/Immunology
    GSK-9772 is a Liver X Receptor (LXR) modulator of the N-phenyl tertiary amine class (NPTAs) with high affinity for LXR β ligand (IC50=30 nM). GSK-9772 has anti-inflammatory activity by binding to LXR, specifically by interacting with the region associated with the transcriptional repression function of the receptor, thereby inhibiting the expression of pro-inflammatory genes. GSK-9772 can be used in the study of inflammatory and neurodegenerative diseases .
    GSK-9772
  • HY-N6802

    Keap1-Nrf2 Cancer
    Tigloylgomisin H is a lignan isolated from the fruits of S. chinensis, can induce quinone reductase (QR) activity in Hepa1c1c7 mouse hepatocarcinoma cells. Tigloylgomisin H functions as a monofunctional inducer that specifically upregulates phase II detoxification enzyme NQO1 through the NF-E2-related factor 2 (Nrf2)-ARE pathway, thus represents a potential liver cancer prevention agent .
    Tigloylgomisin H
  • HY-34596

    Biochemical Assay Reagents Amyloid-β Neurological Disease Metabolic Disease
    4-Hydroxyindole is a type of hydroxyindole in which the 1H-indole at position 4 is substituted by a hydroxyl group. 4-Hydroxyindole serves as an important raw material or intermediate in the synthesis of pharmaceutical products and industrial polymers. 4-Hydroxyindole inhibits amyloid fibrillization and induces liver function impairment, thyroid abnormalities, and blood glucose fluctuations in mice. 4-Hydroxyindole holds potential for research in neurodegenerative diseases and metabolic disorders .
    4-Hydroxyindole
  • HY-N6850
    Calenduloside E
    1 Publications Verification

    Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR Cardiovascular Disease Inflammation/Immunology
    Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses .
    Calenduloside E

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: